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Molecular mechanismThe rapid increase in multi-drug resistant bacteria has resulted in previously discontinued treatments being
revisited. Aminoglycosides are effective “old” antibacterial agents that fall within this category. Despite extensive
usage and understanding of their intracellular targets, there is limited mechanistic knowledge regarding how
aminoglycosides penetrate bacterial membranes. Thus, the activity of two well-known aminoglycosides, kana-
mycin A and neomycin B, towards a bacterial mimetic membrane (DMPC:DMPG (4:1)) was examined using a
Quartz CrystalMicrobalancewithDissipationmonitoring (QCM-D). Themacroscopic effect of increasing the ami-
noglycoside concentration showed that kanamycin A exerts a threshold response, switching from binding to the
membrane to disruption of the surface. Neomycin B, however, disrupted themembrane at all concentrations ex-
amined. At concentrations above the threshold value observed for kanamycin A, both aminoglycosides revealed
similar mechanistic details. That is, they both inserted into the bacterial mimetic lipid bilayer, prior to disruption
via loss of materials, presumably aminoglycoside-membrane composites. Depth proﬁle analysis of this mem-
brane interaction was achieved using the overtones of the quartz crystal sensor. The measured data is consistent
with a two-stage process inwhich insertion of the aminoglycoside precedes the ‘detergent-like’ removal ofmem-
branes from the sensor. The results of this study contribute to the insight required for aminoglycosides to be
reconsidered as active antimicrobial agents/co-agents by providing details of activity at the bacterial membrane.
Kanamycin and neomycin still offer potential as antimicrobial therapeutics for the future and the QCM-Dmethod
illustrates great promise for screening new antibacterial or antiviral drug candidates.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The uncontrolled use of antibiotics over almost a century has result-
ed in bacterialmutations and resistance towards existing treatments. As
a consequence, many antibiotics have been rendered ineffective and
there is now an urgent need for new classes of antibiotics to combat
multi-drug resistant (MDR) organisms [1]. Aminoglycosides were ﬁrst
introduced as antibacterial therapeutics in the 1940's as they showed
activities towards both Gram-negative and Gram-positive bacteria [2].
However, with the emergence of equally potent but less toxic antibi-
otics, the use of aminoglycosides as antibiotics fell out of favor. But,
with the increasing threat of MDR bacteria [3–7] and the decline in
new antibiotics approved to help combat this global challenge [8],ia), Lisa.Martin@monash.edu
otechnology, 31 Biopolis Way,
aduate School for Integrative
re 117456, Singapore.aminoglycosides are being revisited [9–17]. Because aminoglycosides
have been able to largely evade bacterial resistance due to their
waned use, it has made them a safer choice [9–17]. In particular,
approaches in which aminoglycosides are used in combination therapy
with other antibiotics is an emerging strategy [9–18].
Aminoglycosides [19] are a large family of amino-modiﬁed sugars, of
which streptomycin is the most well-knownmember [20]. Two related
derivatives are kanamycin A and neomycin B. A common structural
feature shared by these two aminoglycosides is the presence of the
central 2-deoxystreptamine (2-DOS) ring (Fig. 1). In kanamycin, the
2-DOS core is glycosylated with amino sugars at positions 4 and 6,
while neomycin features amino sugars at positions 4 and 5, as shown
in Fig. 1 [19].
Aminoglycosides are especially active towards Gram-negative
bacteria and their primary bactericidal mode-of-action is through
binding to the 16S rRNA component of the 30s subunit of the bacterial
ribosome [21–23]. This causes miscoding of genetic material during
the translation of mRNA in the 16S rRNA mer, thereby interfering with
protein synthesis. Aminoglycosides are also capable of binding to a
wide range of other RNA-based structures, including catalytic RNAs
Fig. 1.Molecular structures of 2-deoxystreptamine (2-DOS), kanamycin A and neomycin B.
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and Tar in HIV [27,28].
They have been found to promote the cleavage of hairpin ribozymes,
to indirectly interfere with the splicing of the td intron, to act as
enhancers of the catalytic properties of group I intron ribozymes, and
even to inhibit ribozymes such as the hammerhead and hepatitis delta
virus (HDV) ribozymes [21]. Neomycin B has also been reported to
catalyze phosphodiester hydrolysis in a model RNA system,
adenylyl(3′–5′)adenosine (ApA) [29], and RNA oligonucleotides [30].
However, in order for the aminoglycosides to reach these and other
intracellular targets they must ﬁrst penetrate the cell membrane.
Several biophysical studies have been conducted to assess the
aminoglycosides' ability to permeate biological membranes [31] and
phospholipids [32]. Toxicity towards cochlear [33–37] and renal cells
[34,36] has been noted, with neomycin B showing the highest ototoxic-
ity and nephrotoxicity. The fact that neomycin B has the highest positive
charge among the various aminoglycosides (at physiological pH)
indicates that charge may play a role in the interaction of the aminogly-
cosides with membranes [37–39]. Moreover, the ability of aminoglyco-
sides to cause liposomal aggregation by binding to anionic lipid head
groups via electrostatic attraction has also been documented [40–42].
Earlier studies exploring the mode of action of aminoglycosides report-
ed blebs along the cell walls of the Escherichia coli bacteria after amino-
glycoside administration [43,44]. More recently, it has been established
that aminoglycosides can form channels or ﬁssures in the outer cell
membrane [45], allowing their inﬂux into the cytoplasm, followed by
targeting of the bacterial ribosomes. Hancock and co-workers have
shown that these polycationic aminoglycosides can also be taken up
across the E. coli outer membrane by another mechanism termed as
self-promoted uptake pathway [38,39,46,47]. Despite signiﬁcant
knowledge of aminoglycoside intracellular activity, the mechanism of
uptake of aminoglycosides is less well understood. Clearly aminoglyco-
sides must be able to pass across the biological membrane in order to
achieve effective intracellular activity.
In this study, we explore the activity of two well-known aminogly-
cosides, kanamycin A and neomycin B, towards bacterialmimeticmem-
branes using a sensitive platform device: a quartz crystal microbalance
with dissipation monitoring (QCM-D) [48,49]. This biophysical
technique enables exploration of the membrane activity of these two
aminoglycoside derivatives in real-time. Aminoglycosides are them-
selves facing an inevitable threat of resistance,mainly fromaminoglyco-
side modifying enzymes (mediating selective resistance) and 16S rRNA
methyltransferases (conferring class-wide resistance) [12]. Their stillremain outstanding questions on themode of action of aminoglycosides
[9,11–15]. New aminoglycoside derivatives, chemically modiﬁed to
circumvent resistance, can be foreseen to play an important role as
antibiotics in the future [9,11–15]. The data provide additional insights
that may assist medicinal chemists with the development of this next
generation of aminoglycoside-based antibacterial therapeutics.
2. Experimental section
2.1. Chemicals
Neomycin B trisulfate, kanamycin A sulfate, sodium chloride,
potassium phosphate monobasic and potassium phosphate dibasic,
cholesterol, chloroform (≥99.8%) and methanol (≥99.9%) were all
purchased from Sigma-Aldrich (St. Louis, USA) and usedwithout puriﬁ-
cation. The synthetic phospholipid derivatives, 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-
phospho-rac-(1-glycerol) (sodium salt) (DMPG), were purchased
from Avanti Polar Lipids (Alabaster, USA) and 3-mercaptopropionic
acid (MPA) from Fluka. Ultrapure water with an initial resistivity of
18.2 MΩ.cmwasused for all experiments. Phosphate buffered saline so-
lutions (20 mM KH2PO4 and K2HPO4, pH 6.9 ± 0.1) containing either
100 mM (high-salt PBS) or 30 mM (low-salt PBS) sodium chloride
were prepared in water.
2.2. Instrumentation and methods
A lipid composition of DMPC/DMPG (4:1 v/v) was used for liposome
preparation (see Supporting Information for details), following our
previously published procedure [50,51]. The Quartz Crystal Microbal-
ance with Dissipation Monitoring (QCM-D) measurements were
performed using E4 system with ﬂow cells (Q-Sense, Västra Frölunda,
Sweden). The polished, gold-coated, AT-cut quartz chips with a funda-
mental oscillating frequency of ca. 5 MHz, were used as sensor crystals.
The sensors were treated with mercaptopropionic acid to create a self-
assembled carboxylate monolayer prior to the introduction of the
liposomes as described in the Supporting Information. All QCM-D
experiments were conducted at 19.10 ± 0.05 °C [52], in triplicate,
using established experimental protocols also used for peptides–
membrane interactions (see Supporting Information for details) [51,
53–55]. Concentration studies were carried out using 1, 10 and 15 μM
solutions of kanamycin A and neomycin B in high-salt PBS. For a typical
QCM-D experiments, the relative changes in resonance frequency (Δf)
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ed at the 1st, 3rd, 5th, 7th and 9th harmonics. The primary Δf− t and
ΔD− t QCM-D datawere analyzed usingOriginPro 8 (OriginLab, North-
ampton, USA) and Δf vs ΔD graphs were used for further analysis. Data
for the 1st harmonic (i.e., fundamental frequency of the crystal) were
not included in the analysis as it is generally unreliable, being
inﬂuenced by the ﬂow of the solution through the QCM chamber [55].
For discussion purposes, only the 7th harmonic data plots have been
presented, unless otherwise stated. A typical experiment is illustrated
in Fig S1.Fig. 3. Δf-t traces from the QCM-D monitoring of the interaction of neomycin B with a
DMPC/DMPG (4:1) membrane showing the effect of concentration on membrane uptake.3. Results and discussion
The interaction of kanamycin A and neomycin B with phospholipid
bilayers consisting of DMPC/DMPG (4:1) was analyzed using the
QCM-D. The anionic DMPC/DMPG (4:1) lipid combination is recognized
as being a good biomimetic for the prokaryotic cell membrane [56,57],
particularly the Gram-positive bacterial membrane [58,59]. The
frequency change (Δf) from the QCM-D is related to the change in
mass [60], while the dissipation output (ΔD) can be used for the
qualitative proﬁling of structural changes in the bilayer. A decrease in
Δf value implies the addition of mass onto the sensor, whereas an
increase in ΔD indicates that the lipid bilayer is becoming less rigid,
loosening or thickening [60–63].
The effect of the addition of kanamycin A on the lipidmembranewas
followed by measuring the Δf vs. t data, which showed the concentra-
tion dependence depicted in Fig. 2. The data was normalized prior to
the addition of the aminoglycoside. When introduced into the chamber
at 1 μM concentration, kanamycin A was found to slowly add onto the
phospholipid membrane. As can be gauged from the respective Δf− t
traces (Fig. 2), the oscillation frequency of the sensor decreased with
time upon addition of kanamycin A until all the solution was added
(~17 min). After this time, the ﬂow was ceased and the samples were
incubated for 30 min. At higher concentrations (10 and 15 μM),
however, rapid removal of material from the membrane-coated sensor
occurred after the initial mass addition to ~-5 Hz. At these higher
concentrations the threshold for the initial binding of kanamycin
(Δf ≈ -4–5 Hz) was similar, however a second ‘disruption’ phase
corresponding to a greater mass removal from the lipid membrane
was observed at 15 μM, suggesting a concentration dependence.
A similar biphasic trend of rapid initial mass uptake and material
removal thereafter was observed for neomycin B, at all the concentra-
tions studied (Fig. 3). In contrast to kanamycin, however, there was no
concentration threshold observed, although the process was character-
ized by insertion to 4–5 Hz, followed by disruption. Interestingly, asFig. 2.Δf-t traces fromQCM-Dmonitoring of the interaction of kanamycin Awith a DMPC/
DMPG (4:1) membrane showing the effect of concentration on membrane uptake.observed for kanamycin A, membrane disruption was greatest at the
highest concentration studied (15 μM), as shown in Fig. 3.
QCM-D experiments are also able to provide depth proﬁling via
analysis of frequency changes at different harmonics of the QCM-D
sensor [51,53–55]. Each harmonic probes a deﬁned distance away
from the surface of the sensor. This distance is inversely proportional
to the frequency of the harmonic [64]. For example, the higher
harmonics (7th and 9th) probe close to the sensor surface, whereas
the lower harmonics (3rd and 5th) probe further away. Thus, probing
the harmonics in a QCM-D experiment can provide a method to assess
the nature of the interaction of the aminoglycoside with themembrane
layer, i.e., surface vs. trans-membrane binding. The spread of the
harmonics (from the 3rd to the 9th) in Δf − t and ΔD − t plots for
neomycin B (1–15 μM) and kanamycin A (10 and 15 μM) was similar,
as illustrated in Fig. 4 where the 3rd, 5th, 7th and 9th harmonics are
shown. This initial overview illustrates the similarities between kana-
mycin and neomycin in terms of their interaction with the membrane
layer. The Δf− t data for kanamycin (Fig. 4a) and neomycin (Fig. 4b)
both show a decrease in frequency to ~5 Hz, with overlap of the
harmonics. Thus, the initial phase of the aminoglycoside–membrane
interaction is independent of the distance from the sensor, consistent
with mass addition equally across the membrane, i.e., in a trans-
membrane fashion. However, in the second phase, beginning at
~5 min, there is the loss of mass (Δf increases) from the sensor, which
is characterized by a differential response depending on the harmonic
used to sense the frequency. Thus, the 3rd harmonic, which probes
the furthest distance, shows the largest increase in frequency, whereas
the 9th harmonic plots displayed the lowest increments (Fig. 4). In the
second phase, more mass is being removed from the surface of the
membrane.
Similar trends were observed for the ΔD − t plots shown in
Fig. 4(c) and (d). In these cases, the largest decrease in dissipation was
observed for the 3rd harmonic, with progressively smaller decreases
in dissipation energy found for higher harmonics. These decreases in
ΔD are consistent with a loss of membrane (or aminoglycoside–
membrane materials), since the sensor would be expected to become
less viscoelastic in response to membrane loss. The data provided by
the different harmonics indicate more material being removed from
the membrane surface with time, resulting in a decrease in membrane
thickness.
Returning to the kanamycin data obtained at 1 μM concentration,
only a small displacement of the 3rd harmonic is observed, with the
other harmonics almost overlapping (Fig. 5). As discussed above for
the initial process, the overlapping harmonics suggest that the added
aminoglycoside is inserting in a trans-membrane manner, however
the displacement of the 3rd harmonic suggests that the surface of the
membrane is affected slightly differently. There is always the possibly
Fig. 4. QCM-Dmonitoring of kanamycin A (10 μM); (a) Δf-t; (c) ΔD-t plots, and neomycin B (10 μM); (b) Δf-t; (d) ΔD-t traces, showing the uptake on a DMPC/DMPG (4:1) bacterial mi-
metic membranes. The response of the 3rd, 5th, 7th and 9th harmonics of the QCM-D sensors are each shown in these panels.
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ded liposomes could be present that did not burst during themembrane
deposition. However, the small but clear harmonic effect observed in
the ΔD − t values suggests that a two-phase process similar to that
observed with the higher aminoglycoside concentrations is occurring.
Thus, the responses of the harmonics shown in Fig. 5b (maxima follow-
ed by decreases in ΔD − t values) are consistent with insertion of
kanamycin into themembrane, albeit with slightlymore binding occur-
ring at the surface of themembrane, followed by a small loss of material
from the surface and a loosening of themembrane layer. It appears that
the data in Fig. 5 were captured at just the right concentration for the
concentration threshold interaction to be observed.Fig. 5. QCM-D monitoring of kanamycin A (1 μM) uptake on a DMPC/DMPG (4:1) membrane wThe temporal frequency and dissipation changes can be combined as
Δf-ΔD traces to provide greater insight into changes in the structural
integrity of the lipid bilayer occurring during mass addition/removal
processes.We have previously shown that these traces provide a unique
“ﬁngerprint” characteristic of the mode of interaction of a small mole-
cule or biomolecule with the supported phospholipid bilayer-modiﬁed
sensor [51,53,54,65]. The Δf-ΔD ﬁngerprints for both kanamycin A and
neomycin B are shown in Fig. 6 (7th harmonic data shown only).
In these plots, the origin represents the starting point for both
aminoglycosides. Initially, the binding of each compound is indicated
by the observed frequency decrease, i.e., the tracemoves from the origin
to a maximum value, or ‘turning point’, that appears characteristic ofith (a) Δf-t and (b) ΔD-t plots showing the effect on the 3rd, 5th, 7th and 9th harmonics.
Fig. 6. Energy dissipation (ΔD) vs. frequency (Δf) dependence of the interaction of (a) kanamycin A and (b) neomycin Bwith a DMPC/DMPG (4:1)membrane. The x- and y-axis represent
Δf and ΔD (10-6) values, respectively.
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almost reverse in direction and continue towards the lower quadrant
(positive frequency and negative dissipation region), indicating a loss
of materials from the sensor. In summary, the interaction between
these aminoglycosides and the model phospholipid membrane is
biphasic in nature. The initial decrease in Δf, with minimal changes in
ΔD values, followed by a large decrease in ΔD along with an increase
in Δf values is characteristic of trans-membrane insertion followed by
membrane disruption.
Qualitative evaluation of the rates of association/dissociation of
kanamycin A and neomycin B was also carried out via time dependent
analysis of the ﬁrst-order derivative of the Δf− t curves (∂Δf/∂t vs. t).
These kinetic proﬁles are shown in Fig. 7 for two concentrations
(1 and 10 μM) of each of the aminoglycosides and over the period of
time in which material addition and removal processes occurred. These
derivative traces reveal an extremely slow mass uptake (b1 Hz/min)
of kanamycin A at 1 μM concentration, with the rate of mass addition
increasing in the order kanamycin A (1 μM) ≪ neomycin
B (1 μM) b kanamycin A (10 μM)≈ neomycin B (10 μM). At the higher
concentrations of kanamycin A and neomycin B, removal of thematerial
from membrane was ca. 3-fold faster for neomycin B compared to
kanamycin A. Interestingly, at 10 μM concentration, the initial insertion
step occurred at a similar rate for both aminoglycosides (~7 Hz/min),
whereas the disruption that followed was faster for neomycin BFig. 7. First-order derivative of 7th harmonic Δf-t traces vs. time for the interaction of
10 μM kanamycin A and neomycin B with a DMPC/DMPG (4:1) membrane, as plotted
against time. Data for time ≥ 20 min has been omitted for clarity.(~20 Hz/min) compared to kanamycin A (~7 Hz/min). The data for
neomycin B at 1 μM also showed a similar trend, with the rate of
disruption approximately two times greater than the rate of insertion
into the membrane.
Both kanamycin A (+4) and neomycin B (+6) are positively
charged at pH = 6.90. Thus, the initial rapid association and insertion
into the lipid membrane could be due to strong electrostatic attraction
with the anionic membrane surface (DMPC/DMPG (4:1)). In addition,
the DMPG component contains a glycerol group that could assist in
hydrogen-bonding interactions with the cationic aminoglycosides,
although we have no direct evidence of these interactions. The associa-
tive binding of the aminoglycosides is not a favorable interaction in the
membrane, andwe believe that local disorder in the lipid bilayer results,
followed by removal of material. Thus, disruption of bacterial mimetic
DMPC/DMPG (4:1) membrane by kanamycin A and neomycin B is a
biphasic process, as illustrated in Fig. 8 [53–55,66]. The individual
polycationic aminoglycoside molecules insert into the membrane
surface in a trans-membrane orientation, until a threshold concentra-
tion is reached, whereupon the combined interactions between the
molecules and the lipid membrane (electrostatics, hydrogen-bonding)
result in destabilization of the membrane and accretion of material.
4. Conclusion
QCM-D analysis indicates that the two well-known aminoglyco-
sides, kanamycin A and neomycin B, interact with a bacterial mimetic
membrane (DMPC/DMPG (4:1)) via a two-stage mechanism. Initial
aminoglycoside insertion into the membrane is rapid and occurs in a
trans-membrane fashion. This is followed by an equally facile mem-
brane disruption stage once a critical concentration threshold is
reached. Loss of membrane material occurs more from the surface of
the membrane than the interior. Kanamycin A and neomycin B both
show similar rates of insertion into the anionic membrane surface,
however they differ slightly in their rates of membrane disruption.
Neomycin B causes a greater degree of membrane disruption, which is
argued to be due to its greater cationic charge. It is hypothesized that
electrostatic interactions of the polycationic aminoglycoside with the
anionicmembrane surface and intermolecular hydrogen-bonding inter-
actions between the lipid membrane and the charged aminoglycoside
molecules contribute to local disorder and stresswithin the lipid bilayer,
leading to the membrane damage and removal of material. If this is
indeed the case, incorporation of functional groups to enhance these
interactions could produce compounds with enhanced potency, which
might serve as the basis for new antimicrobial therapeutic treatments
urgently needed to combat the rapid growing population of drug-
resistant viruses and bacteria. With this in mind, we are currently
Fig. 8.Proposed biphasicmode-of-action for kanamycin A andneomycin B (represented as red ribbons) onDMPC/DMPG (4:1) lipidmembranes (yellow-blue ribbons). Themechanism for
these aminoglycosides is initially insertion, followed by disruption of the membrane layer.
390 T. Joshi et al. / Biochimica et Biophysica Acta 1848 (2015) 385–391conducting in-depthQCM-D investigations of the interactions of several
such modiﬁed aminoglycoside derivatives with bacterial mimetic
membranes.
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QCM-D Quartz Crystal Microbalance with Dissipation monitoring
RNA Ribonucleic acid
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